Elevance Health (ELV)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
$418.86+2.62%
Close 2026-07-07 · 1-day change
Reading ELV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ELV free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
Reading ELV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ELV free→QuarterlyIQ Insights · ELV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings. FORWARD-LOOKING STATEMENTS This document contains certai…
or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
Regulation FD Disclosure Officers of Elevance Health, Inc. (the “Company”) expect to speak with investors and analysts over the next week. During these meetings, Company officers will reaffirm adjusted shareholders’ earnings for full year 2026 to be at least $25.50 per diluted share. The Company also will reaffirm its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. As reported in a Current Report on Form 8-K filed by the Company on March 2, 2026, the Company was no…
Regulation FD Disclosure On February 27, 2026, Elevance Health, Inc. (the “Company”) was notified by the Centers for Medicare & Medicaid Services (“CMS”) of its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company’s Medicare Advantage-Prescription Drug (“MA-PD”) plans and suspending certain communication activities to Medicare beneficiaries. The sanctions are scheduled to take effect on March 31, 2026 unless CMS determines that the issues id…
Executive Vice President and President of Carelon — Peter D. Haytaian: Mr. Haytaian is transitioning from his role to devote more time to family commitments.
hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings. FORWARD-LOOKING STATEMENTS This document contains certai…
or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
Director — Amy W. Schulman: Elevance Health, Inc. appointed Amy W. Schulman as an independent director and to its Audit and Finance Committees.
hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings. FORWARD-LOOKING STATEMENTS This document contains certai…
or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
Other Events. The Notes Offering On September 15, 2025, Elevance Health, Inc. (the “Company”) closed its sale of $750 million aggregate principal amount of its 4.000% Notes due 2028 (the “2028 Notes”), $750 million aggregate principal amount of its 4.600% Notes due 2032 (the “2032 Notes”), $1,000 million aggregate principal amount of its 5.000% Notes due 2036 (the “2036 Notes”) and $500 million aggregate principal amount of its 5.700% Notes due 2055 (the “2055 Notes” and, together with the 20…
hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings. FORWARD-LOOKING STATEMENTS This document contains certai…
Director — Steven H. Collis: Mr. Steven H. Collis was elected as an independent director and appointed to the Audit and Finance Committees.
or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings. FORWARD-LOOKING STATEMENTS This document contains certai…
or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
Results of Operations and Financial Condition.
hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings. FORWARD-LOOKING STATEMENTS This document contains certai…
hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings. FORWARD-LOOKING STATEMENTS This document contains certai…
or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
Other Events. The Notes Offering On October 31, 2024, Elevance Health, Inc. (the “Company”) closed its sale of $350 million aggregate principal amount of its 4.500% Notes due 2026 (the “2026 Notes”), $750 million aggregate principal amount of its 4.750% Notes due 2030 (the “2030 Notes”), $750 million aggregate principal amount of its 4.950% Notes due 2031 (the “2031 Notes”), $1,200 million aggregate principal amount of its 5.200% Notes due 2035 (the “2035 Notes”), $1,350 million aggregate pri…
or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings. FORWARD-LOOKING STATEMENTS This document contains certai…
Other Events. The Notes Offering On May 30, 2024, Elevance Health, Inc. (formerly known as Anthem, Inc.) (the “Company”) closed its sale of $600 million aggregate principal amount of its 5.150% Notes due 2029 (the “2029 Notes”), $1,000 million aggregate principal amount of its 5.375% Notes due 2034 (the “2034 Notes”) and $1,000 million aggregate principal amount of its 5.650% Notes due 2054 (the “2054 Notes” and, together with the 2029 Notes and the 2034 Notes, the “Notes”) pursuant to an Und…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.